Samantha Peacock

Samantha Peacock's representative experience includes advising:

Venture Capital – Investor Side

• atai Life Sciences on its strategic investment and subsequent acquisition of Beckley Psytech, a private clinical-stage biotechnology company.
• Patient Square Capital on its US$226.5 million lead investment in Apollo Therapeutics’ Series C financing round.
• Octopus Ventures on multiple investments including in Manual, Pencil Biosciences, Vira Health, Awell Health, and Touchlab from pre-seed to Series B stages.
• Hoxton Ventures on its lead investments in Skin Analytics, Bother, Slice, and Luminary ROLI.
• Novo on its Series D and E investments in Quanta Dialysis Technologies, a commercial-stage dialysis device company.
• Citi Ventures on its investment in GoHenry’s US$40 million funding round.
• GIC, alongside JP Morgan and HSBC’s Venture Capital Fund, on their Series B+ investments in Miotech, an ESG data startup.

Venture Capital – Company Side

• OrganOx, a leading organ medical technology company, on its US$142 million primary and secondary equity financing round led by HealthQuest Capital, BGF, and Lauxera Capital Partners.
• Verdiva Bio, a clinical-stage biopharmaceutical company, on its US$410 million Series A financing led by Forbion and General Atlantic.
• WorldRemit on its US$292 million Series E funding round.
• Toqio on its seed funding round led by Seaya and Speedinvest.
• LifeScore on its £11 million Series A financing led by Octopus Ventures and Warner Music Group.
• Aztec Network on its Series B and A funding rounds led by a16z and Paradigm respectively.
• Fertifa Limited, a leading reproductive healthcare benefits provider, on its seed funding round led by Passion Capital.

Healthcare & Life Sciences M&A

• OrganOx on its US$1.5 billion sale to Terumo shortly after its US$142 million equity financing round.
• BC Partners on its sale of a majority stake in Synthon to Goldman Sachs Alternatives.
• Novo Holdings on its acquisition of Benchmark Genetics from Benchmark Holdings plc.
• Norgine on selling a controlling stake to Goldman Sachs Asset Management.
• Lindsay Goldberg on portfolio company MMS’ acquisition of data science company Exploristics.
• TPG on acquiring Doc Generici, a leading Italian generics company.
• Alliance Pharma on acquiring the US-based ScarAway brand.
• Acino on acquiring approximately 30 products across Takeda’s primary care portfolio in MENA and Ukraine.
• Theramex, on CVC’s US$703 million acquisition of women’s healthcare assets from Teva.
• TLS Beta on acquiring a 30% stake in Stamford Devices, an Ireland-based provider.

Major Corporate Transactions

• Actavis on its £306 million acquisition of Auden Mckenzie, increasing its foothold as the largest generics company in the UK.
• Actavis on its divestment of part of its Western European generics sale and marketing business to Aurobindo.
• Actavis UK on its £603 million divestment by Teva to Intas.